Focused on oral therapies for obesity, diabetes and rare diseases, Boston-based Syntis Bio Inc., which raised $15.5 million through seed funding last year, emerged from stealth to advance its synthetic tissue-lining technology and a pipeline of candidates.

Life sciences venture capital company, Brandon Capital, announced the first close of its sixth fund for AU$270 million (US$180 million) during the 2024 Biotechnology Innovation Organization International Convention in San Diego. Fund VI will see Brandon Capital continue to seed new Australian and New Zealand life sciences startups, as well as advance its expansion into international markets, particularly in the U.K., Europe, and the U.S.

Life sciences venture capital company, Brandon Capital, announced the first close of its sixth fund for AU$270 million (US$180 million) during the 2024 Biotechnology Innovation Organization International Convention in San Diego. Fund VI will see Brandon Capital continue to seed new Australian and New Zealand life sciences startups, as well as advance its expansion into international markets, particularly in the U.K., Europe, and the U.S.

Cancer vaccines specialist Infinitopes Precision Immunomics Ltd. announced the closing of a £12.8 million (US$16.1 million) seed round and outlined plans to start a phase I/IIa study of the lead program in the third quarter of this year.

Dynamic Therapeutics Ltd. is looking to commercialize its U-Rhythm technology which it hopes will transform the way hormones are measured. U-Rhythm, a portable device which collects biochemical samples from the patient throughout the day, will significantly change the diagnosis and treatment of many diseases, Stafford Lightman, co-founder of Dynamic Therapeutics told BioWorld.

Revopsis Therapeutics Inc. has closed its first seed funding round, raising $16.5 million that will fund the completion of ongoing IND-enabling studies with its lead candidate, RO-104, for the treatment of neovascular age-related macular degeneration (nAMD). Developed using the company’s proprietary Rev-Mod platform, RO-104 is a potentially first-in-class fully human modular trispecific biologic.

In one of the biggest startups ever, Xaira Therapeutics has launched with more than $1 billion from investors. The financing, according to BioWorld records, is roughly equivalent to Roivant Sciences Inc.’s $1.1 billion raise in August 2017 and Galderma Inc.’s $1 billion private placement in June 2023. Xaira said it plans to leverage advanced machine learning research and expansive data generation to power new models for developing new therapeutics.

In one of the biggest startups ever, Xaira Therapeutics has launched with more than $1 billion from investors. The financing, according to BioWorld records, is roughly equivalent to Roivant Sciences Inc.’s $1.1 billion raise in August 2017 and Galderma Inc.’s $1 billion private placement in June 2023.

Newco Outrun Therapeutics Ltd. has raised $10 million in a seed round to develop small-molecule E3 ubiquitin ligase inhibitors that prevent programmed protein degradation. The lead program targeting an E3 ligase that tags a tumor suppressor protein for destruction will now advance to preclinical development.

Newco Outrun Therapeutics Ltd. has raised $10 million in a seed round to develop small-molecule E3 ubiquitin ligase inhibitors that prevent programmed protein degradation. The lead program targeting an E3 ligase that tags a tumor suppressor protein for destruction will now advance to preclinical development.